AR111830A1 - Anticuerpos monoclonales antagonistas contra cd40 y sus usos - Google Patents
Anticuerpos monoclonales antagonistas contra cd40 y sus usosInfo
- Publication number
- AR111830A1 AR111830A1 ARP180101388A ARP180101388A AR111830A1 AR 111830 A1 AR111830 A1 AR 111830A1 AR P180101388 A ARP180101388 A AR P180101388A AR P180101388 A ARP180101388 A AR P180101388A AR 111830 A1 AR111830 A1 AR 111830A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- seq
- antigen binding
- binding portion
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La descripción proporciona anticuerpos que se fijan a CD40, que incluye un anticuerpo humanizado y un anticuerpo quimérico con dominios Fc diferentes. Los anticuerpos se fijan a CD40 y no exhiben actividad agonista de CD40. Los anticuerpos pueden comprender un dominio Fc de IgG1 modificado y exhibir activación mínima de células dendríticas inmaduras. Composiciones que comprenden anticuerpos, métodos de uso para el tratamiento de enfermedades que incluyen la actividad de CD40, y el uso en la preparación de un medicamento para el tratamiento de una enfermedad que incluye la actividad de CD40. Reivindicación 1: Un anticuerpo aislado, o una porción de fijación al antígeno de este, que se fija específicamente a CD40 humana, en donde dicho anticuerpo comprende una cadena pesada y una cadena liviana, caracterizado porque: dicha cadena pesada comprende una CDR1 que comprende GYTFTDLSMHW (SEQ ID Nº 1), una CDR2 que comprende YITPSSGYTAYNQKFKG (SEQ ID Nº 2), una CDR3 que comprende LILQRGAY (SEQ ID Nº 3) y una región constante de la cadena pesada humana; y dicha cadena liviana comprende una CDR1 que comprende RASKNVDSYGNSFMHW (SEQ ID Nº 4), una CDR2 que comprende RASNLES (SEQ ID Nº 5), y una CDR3 que comprende QQSNEDPLT (SEQ ID Nº 6) y una región constante de la cadena liviana humana; y dicha región constante de la cadena pesada humana es un dominio Fc de IgG1 humana que comprende (1) una mutación en la posición 238 Kabat que reduce la fijación a los receptores Fc g (FcgR), en donde prolina 238 (P238) se muta a uno de los residuos seleccionados del grupo que consiste en lisina, serina, alanina, arginina y triptófano, y en donde el anticuerpo, o una porción de fijación al antígeno de este, tiene una fijación a FcgR reducida; o (2) una alanina sustituida en la posición 297 Kabat. Reivindicación 16: Un ácido nucleico caracterizado porque codifica un anticuerpo aislado, o una porción de fijación al antígeno de este, de acuerdo con cualquiera de las reivindicaciones 1 a 15. Reivindicación 17: Un vector de expresión caracterizado porque comprende la molécula del ácido nucleico de acuerdo con la reivindicación 16. Reivindicación 18: Una célula caracterizada porque está transformada con un vector de expresión de acuerdo con la reivindicación 17. Reivindicación 19: Un método para preparar un anticuerpo anti-CD40 humana, o una porción de fijación al antígeno de este, caracterizado porque comprende: a) expresar el anticuerpo, o la porción de fijación al antígeno de este, en la célula de acuerdo con la reivindicación 18; y b) aislar el anticuerpo, o una porción de fijación al antígeno de este, de la célula.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511079P | 2017-05-25 | 2017-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111830A1 true AR111830A1 (es) | 2019-08-21 |
Family
ID=62567875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101388A AR111830A1 (es) | 2017-05-25 | 2018-05-24 | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11220550B2 (es) |
| EP (1) | EP3630831B1 (es) |
| JP (1) | JP7257335B2 (es) |
| KR (1) | KR102713355B1 (es) |
| CN (1) | CN110621697B (es) |
| AR (1) | AR111830A1 (es) |
| ES (1) | ES2923143T3 (es) |
| TW (1) | TW201902934A (es) |
| WO (1) | WO2018217976A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230125855A (ko) | 2014-11-21 | 2023-08-29 | 브리스톨-마이어스 스큅 컴퍼니 | Cd73에 대항한 항체 및 그의 용도 |
| FI3468997T3 (fi) | 2016-06-08 | 2023-10-31 | Xencor Inc | Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een |
| CN110621697B (zh) | 2017-05-25 | 2023-06-27 | 百时美施贵宝公司 | 拮抗性cd40单克隆抗体及其用途 |
| EP3630832A1 (en) * | 2017-05-25 | 2020-04-08 | Bristol-Myers Squibb Company | MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH |
| CN110719915A (zh) * | 2017-05-25 | 2020-01-21 | 百时美施贵宝公司 | 包含经修饰的重链恒定区的抗体 |
| EA202092302A1 (ru) | 2018-04-02 | 2021-02-02 | Бристол-Майерс Сквибб Компани | Антитела к trem-1 и их применения |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| JP7649744B2 (ja) * | 2018-12-26 | 2025-03-21 | イムチェック セラピューティクス エスエーエス | Ｂｔｎ３ａ結合タンパク質及びその使用 |
| CN113993893A (zh) * | 2019-02-01 | 2022-01-28 | 拉法医疗有限公司 | 新cd40结合抗体 |
| KR102865175B1 (ko) * | 2019-12-19 | 2025-09-30 | 악스톤 바이오사이언시스 코퍼레이션 | 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법 |
| KR20220151189A (ko) * | 2020-03-09 | 2022-11-14 | 브리스톨-마이어스 스큅 컴퍼니 | 증진된 효능제 활성을 갖는 cd40에 대한 항체 |
| CN113388035A (zh) * | 2020-03-13 | 2021-09-14 | 迈威(上海)生物科技股份有限公司 | 特异性针对人tslp的抗体及其应用 |
| JP7523586B2 (ja) * | 2020-05-18 | 2024-07-26 | ブリストル－マイヤーズ スクイブ カンパニー | 改善された薬物動態特性を有する抗体変異体 |
| SI4284512T1 (sl) | 2021-01-28 | 2025-06-30 | Regeneron Pharmaceuticals, Inc. | Sestavki in postopki za zdravljenje sindroma sproščanja citokinov |
| CN116023495B (zh) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | 一种抗cd40纳米抗体及其制备方法与应用 |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB2353887B (en) | 1999-09-04 | 2003-09-24 | Ibm | Speech recognition system |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20080199471A1 (en) | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| DK2471813T3 (en) | 2004-07-15 | 2015-03-02 | Xencor Inc | Optimized Fc variants |
| US20150315284A1 (en) | 2004-11-09 | 2015-11-05 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
| CN101331223A (zh) | 2005-10-14 | 2008-12-24 | 米迪缪尼有限公司 | 细胞展示抗体文库 |
| WO2008091954A2 (en) | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| US8629245B2 (en) | 2007-05-01 | 2014-01-14 | Research Development Foundation | Immunoglobulin Fc libraries |
| JP5809415B2 (ja) | 2007-11-09 | 2015-11-10 | ペレグリン ファーマシューティカルズ，インコーポレーテッド | 抗ｖｅｇｆ抗体の組成物および方法 |
| US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| SG183947A1 (en) | 2010-03-31 | 2012-10-30 | Boehringer Ingelheim Int | Anti-cd40 antibodies |
| US9303083B2 (en) | 2010-10-04 | 2016-04-05 | Riken | Therapeutic agent for malignant tumors expressing MHC class II |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012088461A2 (en) * | 2010-12-23 | 2012-06-28 | Biogen Idec Inc. | Linker peptides and polypeptides comprising same |
| TWI598363B (zh) | 2011-04-21 | 2017-09-11 | 必治妥美雅史谷比公司 | 拮抗ｃｄ４０之抗體多肽 |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| CA2850194C (en) * | 2011-09-30 | 2023-03-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting elimination of antigens |
| EP4624490A3 (en) | 2012-02-09 | 2025-11-05 | Chugai Seiyaku Kabushiki Kaisha | Modified fc region of antibody |
| GB201203051D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| SG11201408646VA (en) | 2012-07-06 | 2015-01-29 | Genmab Bv | Dimeric protein with triple mutations |
| WO2014030728A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | FcγRIIb特異的Fc領域改変体 |
| US20140294812A1 (en) | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| CN113621057A (zh) | 2013-04-02 | 2021-11-09 | 中外制药株式会社 | Fc区变体 |
| GB201308658D0 (en) | 2013-05-14 | 2013-06-26 | Isis Innovation | Antibodies |
| US10435475B2 (en) | 2014-03-07 | 2019-10-08 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize CD40 to treat IBD |
| DK3177643T3 (da) * | 2014-08-04 | 2019-07-15 | Hoffmann La Roche | Bispecifikke T-celle-aktiverende antigenbindende molekyler |
| US20170233485A1 (en) | 2014-08-18 | 2017-08-17 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| JP2017534577A (ja) * | 2014-09-15 | 2017-11-24 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法 |
| KR20230125855A (ko) | 2014-11-21 | 2023-08-29 | 브리스톨-마이어스 스큅 컴퍼니 | Cd73에 대항한 항체 및 그의 용도 |
| UY36692A (es) | 2015-05-29 | 2016-12-30 | Abbvie Inc | Anticuerpos anti-cd40 y usos de los mismos |
| EA201890162A1 (ru) * | 2015-06-29 | 2018-07-31 | Бристол-Маерс Сквибб Компани | Антитела к cd40 с повышенной агонистической активностью |
| EP3313880B1 (en) | 2015-06-29 | 2025-08-06 | Bristol-Myers Squibb Company | Antibodies to cd40 |
| MA43053A (fr) * | 2015-09-30 | 2018-08-08 | Janssen Biotech Inc | Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation |
| CA3037264A1 (en) | 2016-10-06 | 2018-04-12 | Glaxosmithkline Intellectual Property Development Limited | Antibodies with reduced binding to process impurities |
| KR20240151866A (ko) | 2017-03-14 | 2024-10-18 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
| US20200095323A1 (en) | 2017-03-20 | 2020-03-26 | The General Hospital Corporation | MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY |
| CN110621697B (zh) | 2017-05-25 | 2023-06-27 | 百时美施贵宝公司 | 拮抗性cd40单克隆抗体及其用途 |
| CN110719915A (zh) | 2017-05-25 | 2020-01-21 | 百时美施贵宝公司 | 包含经修饰的重链恒定区的抗体 |
| EP3630832A1 (en) | 2017-05-25 | 2020-04-08 | Bristol-Myers Squibb Company | MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| EP3887397A1 (en) | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
-
2018
- 2018-05-24 CN CN201880030151.8A patent/CN110621697B/zh active Active
- 2018-05-24 KR KR1020197034230A patent/KR102713355B1/ko active Active
- 2018-05-24 AR ARP180101388A patent/AR111830A1/es unknown
- 2018-05-24 ES ES18730621T patent/ES2923143T3/es active Active
- 2018-05-24 WO PCT/US2018/034315 patent/WO2018217976A1/en not_active Ceased
- 2018-05-24 EP EP18730621.2A patent/EP3630831B1/en active Active
- 2018-05-24 US US15/988,554 patent/US11220550B2/en active Active
- 2018-05-24 JP JP2019564883A patent/JP7257335B2/ja active Active
- 2018-05-25 TW TW107117879A patent/TW201902934A/zh unknown
-
2021
- 2021-12-23 US US17/561,529 patent/US11613585B2/en active Active
-
2023
- 2023-03-10 US US18/181,849 patent/US20230322941A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020521453A (ja) | 2020-07-27 |
| CN110621697B (zh) | 2023-06-27 |
| US20180340031A1 (en) | 2018-11-29 |
| KR102713355B1 (ko) | 2024-10-02 |
| EP3630831B1 (en) | 2022-06-15 |
| JP7257335B2 (ja) | 2023-04-13 |
| US20220177596A1 (en) | 2022-06-09 |
| WO2018217976A1 (en) | 2018-11-29 |
| EP3630831A1 (en) | 2020-04-08 |
| US11613585B2 (en) | 2023-03-28 |
| US11220550B2 (en) | 2022-01-11 |
| KR20200011937A (ko) | 2020-02-04 |
| TW201902934A (zh) | 2019-01-16 |
| ES2923143T3 (es) | 2022-09-23 |
| CN110621697A (zh) | 2019-12-27 |
| US20230322941A1 (en) | 2023-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111830A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| US20240076375A1 (en) | Anti-TIM-3 Antibodies and Use Thereof | |
| JP7345578B2 (ja) | 新規抗ｐｄ－ｌ１抗体 | |
| CN112351820B (zh) | 双特异性抗psma x抗cd28抗体及其用途 | |
| KR102372274B1 (ko) | 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체 | |
| CN109843923B (zh) | 针对ctla-4的单结构域抗体及其变体 | |
| DK2976361T3 (en) | HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF | |
| JP2018520657A5 (es) | ||
| KR20250097989A (ko) | 공통 항원을 표적화하는 항원-결합 단백질 | |
| JP2022501377A (ja) | 血液悪性腫瘍の処置において使用するための新規の二重特異性抗体 | |
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| KR20190095941A (ko) | 신규 tnfr 효능제 및 이의 용도 | |
| JP2017532037A (ja) | ヒト化抗ｏｘ４０抗体及びその使用 | |
| PE20211605A1 (es) | ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS | |
| KR20200120641A (ko) | Pd-1에 대한 단일-도메인 항체 및 이의 변이체 | |
| RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
| AR103442A1 (es) | Anticuerpos y receptores de antígenos quiméricos específicos de ror1 | |
| EA202191359A1 (ru) | Антагонистические моноклональные антитела к cd40 и их применения | |
| ES2737307T3 (es) | Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer | |
| JP7527281B2 (ja) | 抗体製剤 | |
| US20220162320A1 (en) | Multispecific binding proteins | |
| CN115925929A (zh) | 抗tnfr2单克隆抗体及其应用 | |
| JP2025156298A (ja) | 抗ニューヨーク食道扁平上皮がん１（ｎｙ－ｅｓｏ－１）抗原結合タンパク質およびその使用方法 | |
| CN112625130A (zh) | 抗-tigit抗体及使用之方法 | |
| AR115014A1 (es) | Anticuerpos contra mica y/o micb y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |